Gene:
ORM2
orosomucoid 2

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for ORM2

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs1687390 NC_000009.11:g.117089888G>A, NC_000009.12:g.114327608G>A, NG_012108.1:g.9586G>A
G > A
SNP
No VIP available CA VA
rs2250242 NC_000009.11:g.117103973A>G, NC_000009.12:g.114341693A>G, NM_001317950.1:c.3907T>C, NM_001317952.1:c.3550T>C, NM_030767.5:c.3907T>C, NP_001304879.1:p.Ser1303Pro, NP_001304881.1:p.Ser1184Pro, NP_110394.3:p.Ser1303Pro, XM_005252243.1:c.3907T>C, XM_005252244.1:c.3907T>C, XM_005252244.2:c.3907T>C, XM_005252245.1:c.3907T>C, XM_005252246.1:c.3907T>C, XM_005252247.1:c.3907T>C, XM_005252247.3:c.3907T>C, XM_005252248.1:c.3811T>C, XM_006717294.1:c.3907T>C, XM_011519059.1:c.3907T>C, XM_011519060.1:c.3754T>C, XM_011519061.1:c.3706T>C, XM_011519062.1:c.3664T>C, XM_011519063.1:c.3550T>C, XM_011519065.1:c.3784T>C, XP_005252300.1:p.Ser1303Pro, XP_005252301.1:p.Ser1303Pro, XP_005252302.1:p.Ser1303Pro, XP_005252303.1:p.Ser1303Pro, XP_005252304.1:p.Ser1303Pro, XP_005252305.1:p.Ser1271Pro, XP_006717357.1:p.Ser1303Pro, XP_011517361.1:p.Ser1303Pro, XP_011517362.1:p.Ser1252Pro, XP_011517363.1:p.Ser1236Pro, XP_011517364.1:p.Ser1222Pro, XP_011517365.1:p.Ser1184Pro, XP_011517367.1:p.Ser1262Pro, XR_929844.1:n.4143T>C, XR_929845.1:n.4143T>C, XR_929846.1:n.4036T>C, rs116882987, rs17857447, rs52828574, rs59133154
A > G
SNP
S1303P
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  alpha-1-acid glycoprotein, type 2
Alternate Symbols:  AGP-B; AGP-B'; AGP2
PharmGKB Accession Id: PA32818

Details

Cytogenetic Location: chr9 : q32 - q32
GP mRNA Boundary: chr9 : 117092069 - 117095536
GP Gene Boundary: chr9 : 117082069 - 117098536
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ORM1

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
antineoplastic agents

Curated Information ?

Publications related to ORM2: 5

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer chemotherapy and pharmacology. 2014. Younis Islam R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clinical pharmacology and therapeutics. 2010. Pautas E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of warfarin dose with genes involved in its action and metabolism. Human genetics. 2007. Wadelius Mia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clinical pharmacology and therapeutics. 2006. Colombo Sara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al. PubMed

LinkOuts

NCBI Gene:
5005
OMIM:
138610
UCSC Genome Browser:
NM_000608
RefSeq RNA:
NM_000608
RefSeq Protein:
NP_000599
RefSeq DNA:
NT_008470
UniProtKB:
A1AG2_HUMAN (P19652)
Q5T538_HUMAN (Q5T538)
Ensembl:
ENSG00000228278
GenAtlas:
ORM2
GeneCard:
ORM2
MutDB:
ORM2
HuGE:
ORM2
Comparative Toxicogenomics Database:
5005
ModBase:
P19652
HGNC:
8499

Common Searches